Pfizer Revamps Neuroscience R&D – New Site, New Mandate, New Leadership
Pfizer has thoroughly revamped its approach to neuroscience R&D, emphasizing disease biology and neural circuitry, moving its research team from Groton, Conn. to Cambridge, Mass., and hiring an eminent neuroscientist to lead the group.
You may also be interested in...
The big pharma is evaluating a full spectrum of M&A opportunities, Pfizer Global Innovative Pharma Business President Germano said in an interview. Whether that includes another bid for AstraZeneca remains to be seen, but when it comes to a potential tax inversion deal, he said business is business.
The reorientation of Big Pharma neuroscience R&D toward a biology-driven approach is creating new hope for the treatment of psychiatric disorders.
At a time of resurgent interest in CNS, The Lieber Institute for Brain Development’s capabilities and tissue resources set it apart from other brain research initiatives. The privately backed research lab is focused on translating genetic clues to the cause and course of schizophrenia and related disorders into new treatments.